Related Experiment Video
Updated: Jan 1, 2026
11:27
A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
9.5K
Structural insights for producing CK2α1-specific inhibitors.
Masato Tsuyuguchi1, Tetsuko Nakaniwa2, Akira Hirasawa3
1Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.
Bioorganic & Medicinal Chemistry Letters
|December 21, 2019
Summary
Developing selective CK2α1 inhibitors is challenging due to subtype homology. Hematein shows distinct binding to CK2α1 and CK2α2, offering insights for targeted drug discovery.
Area of Science:
- Biochemistry
- Structural Biology
- Drug Discovery
Background:
- Casein kinase 2 catalytic subunit (CK2α) comprises two subtypes: CK2α1 and CK2α2.
- CK2α1 is a key drug target, while CK2α2 is an off-target, complicating inhibitor development.
- High sequence homology between CK2α1 and CK2α2 hinders the creation of selective ATP-competitive inhibitors.
Purpose of the Study:
- To investigate the distinct binding mechanisms of hematein to CK2α1 and CK2α2.
- To leverage structural insights for the design of CK2α1-selective inhibitors.
- To address the challenge of subtype selectivity in CK2α inhibitor drug discovery.
Main Methods:
- X-ray crystallography was employed to determine the structures of CK2α1 and CK2α2 in complex with hematein.
- Comparative structural analysis of hematein binding to both CK2α subtypes.
Main Results:
- Hematein exhibits distinct binding modes to CK2α1 and CK2α2.
- Structural differences in hematein binding provide a basis for rational inhibitor design.
- CK2α2 acts as an ATP-competitive inhibitor with hematein, unlike CK2α1.
Conclusions:
- Structural elucidation of hematein-CK2α complexes reveals key differences for selective inhibition.
- These findings pave the way for developing novel CK2α1-specific inhibitors.
- Targeting CK2α1 selectivity is achievable through understanding subtype-specific binding interactions.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.7K
11:11Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
7.8K
Related Concept Videos
02:34Enzymes
92.7K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
92.7K
01:30Enzyme Inhibition
90.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
90.8K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
856
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
856
00:49Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.4K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K